Ivan Martinez, MD
Endocrinology, Diabetes & Metabolism · Anaheim Hills, CANPI 1023014800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 519 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,747 and has fallen 66.5% since, to $1,256 in 2025.
Across 519 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- Amgen$1K
- Sanofi-aventis U.S. LLC$723
- AstraZeneca$604
- plus $5K from 33 others
What the payments were for
- Travel & lodging$80%
- Food & beverage$11,292100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 66 | $1,566 |
| Lilly USA, LLC | 63 | $1,330 |
| AbbVie | 49 | $1,179 |
| Amgen(2 entities) | 30 | $1,075 |
| Sanofi-aventis U.S. LLC | 38 | $723 |
| AstraZeneca | 32 | $604 |
| Novo Nordisk | 32 | $582 |
| Mannkind Corporation | 31 | $533 |
| Boehringer Ingelheim | 24 | $485 |
| Bayer | 24 | $457 |
| Corcept Therapeutics | 15 | $429 |
| Merck | 16 | $392 |
| Antares Pharma, Inc. | 23 | $360 |
| Johnson & Johnson | 10 | $247 |
| Abbott | 12 | $244 |
| Dexcom, Inc. | 14 | $232 |
| Ascendis Pharma Endocrinology Inc | 3 | $162 |
| Halozyme Inc | 5 | $90 |
| Tolmar, Inc. | 5 | $83 |
| Novartis | 3 | $77 |
| Amneal Pharmaceuticals LLC | 3 | $56 |
| Verity Pharmaceuticals Inc. | 1 | $54 |
| Medtronic | 2 | $50 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Madrigal Pharmaceuticals | 1 | $30 |
| IBSA Pharma Inc. | 2 | $29 |
| Cequr Corporation | 1 | $28 |
| Companion Medical, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Valeritas, Inc. | 1 | $15 |
| Vivus LLC | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,343 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $174,016 |
| TrulicityDulaglutide | 136 | $156,253 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $61,718 |
| JardianceEmpagliflozin | 52 | $56,069 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 46 | $50,763 |
| FarxigaDapagliflozin Propanediol | 34 | $39,951 |
| MounjaroTirzepatide | 36 | $36,609 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $36,538 |
| JanuviaSitagliptin Phosphate | 15 | $24,730 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $22,380 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $21,494 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $21,197 |
| RybelsusSemaglutide | 21 | $19,137 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $18,768 |
| TrintellixVortioxetine Hydrobromide | 11 | $16,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,330 | $197,373184 claims |
| Novo NordiskOzempic, Rybelsus | $582 | $193,153168 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $485 | $141,030132 claims |
| MerckJanumet, Januvia, Steglatro | $392 | $65,47768 claims |
| AstraZenecaFarxiga | $604 | $39,95134 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $723 | $20,44633 claims |
| AbbVieSynthroid | $1,179 | $10,930131 claims |
| Johnson & JohnsonXarelto | $247 | $6,28612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $2,299182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Anaheim Hills
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.